Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Background Venous thromboembolism (VTE) remains the third leading cause of acute
cardiovascular syndrome following myocardial infarction and ischemic stroke. The global …

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to
warfarin reduces the risk of post‐thrombotic syndrome (PTS) after deep vein thrombosis …

Introduction Postthrombotic syndrome (PTS) remains associated with significant clinical and
economic burden. This study aimed to investigate known and novel predictors of the …

Deep vein thrombosis (DVT) frequently leads to post-thrombotic syndrome (PTS) which is
challenging to predict and prevent. Identifying those at high risk of developing PTS may help …

The incidence of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis
(DVT) treated with direct oral anticoagulants (DOACs) remains a matter of debate. Hence …

Los anticoagulantes orales directos han surgido como una de las herramientas que ha
cambiado el manejo de la enfermedad trombótica en los últimos 15 años. Sus ventajas …

Background Post-thrombotic syndrome (PTS) is one of the most frequent complications of
venous thromboembolism (VTE) leading to considerable morbidity and cost. Apart from …

Background Post-thrombotic syndrome (PTS) is common in patients with deep vein
thrombosis (DVT). It is unclear if different types of anticoagulant therapies (eg vitamin K …